This study is exploring a new medicine called ivosidenib for adults with certain cancers and liver or kidney problems. *Ivosidenib* is a drug designed to help people with cancers that have a specific change in their genes, called an *IDH1 mutation*. Participants will be divided into five groups based on their liver and kidney function. The study involves several visits during the first and second months, then less frequently. Each treatment cycle lasts 28 days, and the study will continue until it ends. Participants will have check-ups, including blood tests, heart checks (*ECG*), vital sign monitoring, and physical exams.

• This study requires multiple visits, especially in the first two months.
• Participants may be taking the study medication for a long time.
• Participants will have regular health checks, including blood and heart tests.

Eligibility involves having specific types of cancer with an IDH1 mutation and certain liver or kidney function levels. People who recently had stem cell transplants, certain heart conditions, or other specific health issues may not be eligible.